On 14 July 2025, the World Health Organization (WHO) released new HIV prevention guidelines at the 13th International AIDS Society (IAS) Conference. The 13th International AIDS Society (IAS) Conference was held in Kigali, Rwanda. WHO recommended lenacapavir, a long-acting antiretroviral drug, for high-risk groups and areas with high HIV infection rates. Lenacapavir (LEN), developed by Gilead Sciences, is the first capsid inhibitor approved for pre-exposure prophylaxis (PrEP) as a twice-yearly injectable. Initially approved for HIV treatment in 2022, LEN showed near-complete protection in prevention trials. The WHO called it the most effective alternative in absence of an HIV vaccine.
This Question is Also Available in:
ಕನ್ನಡहिन्दीमराठी